Advanced search

731 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	29/05	BU
FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	29/05	GL
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	21/05	BU
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	21/05	GL
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update	16/05	DJ
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial	16/05	DJ
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity	16/05	BU
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity	16/05	GL
Roche: positive CHMP opinion for Alecensa	26/04	CF
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer	19/04	GL
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	19/04	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	17/04	BU
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS	17/04	GL
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	15/04	BU
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study	15/04	GL
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08/04	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06/03	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care	05/03	GL
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	26/02	BU
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies	26/02	GL
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	19/02	AQ
Roche: FDA approves allergy treatment	16/02	CF
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	16/02	GL
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	16/02	BU
New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	01/02	AQ
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)	01/02	BU
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	01/02	GL
Roche cancer immunotherapy receives new EU approval	17/01	AQ
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types	16/01	GL
FDA grants priority review to omalizumab for food allergies	21/12	AQ
Roche - FDA grants priority review to Xolair for children and adults with food allergies based on positive National Institutes of Health phase III study results	20/12	AQ
Roche's Xolair Granted FDA Priority Review	19/12	DJ
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results	19/12	GL
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results	19/12	BU
New data for Roche s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma	12/12	AQ
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma	11/12	GL
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma	11/12	BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A	09/12	AQ
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A	09/12	BU
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A	09/12	GL
Roche's Inavolisib Breast Cancer Drug Gets Positive Results	08/12	DJ
Roche: positive data for Kadcyla in breast cancer	08/12	CF
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment	08/12	GL
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	08/12	GL
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment	08/12	BU
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	08/12	BU
Roche to advance novel obesity and diabetes treatments	05/12	AQ
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	05/12	GL
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	05/12	BU
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update	04/12	DJ

No results for this search

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer